Back to List

Chiesi Farmaceutici

We work to guarantee effective and safe cures by exploring new frontiers in treatment and care and expanding patients’ access to care in key emerging countries.

We care for newborns: we develop medical solutions in partnership with caregivers to reduce the hospitalization of premature babies and improve their short and long-term outcomes. We develop models to improve access to care for newborns in the poorest countries.

We care for patients with serious non-communicable diseases-in particular respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD) – by developing sustainable therapeutic solutions, both drugs and services, which improve their state of health and quality of life. We engage in helping healthcare professionals in preventing and managing these chronic conditions.

We care for people affected by rare diseases and other difficulto treat non-communicable conditions. We engage in the research and development of drugs that cure the diseases or significantly diminish the burden of suffering of these patients and their families; we partner with the healthcare system to reduce diagnosis time and facilitate access to care.

We invest a considerable portion of our resources in research and development to foster scientific knowledge and create a network of top class scientists engaged in finding solutions to patients’ suffering.

Through Chiesi Foundation Onlus, which is a non-profit organization founded in 2005 as an expression of the social responsibility of the Chiesi Group, we aim at improving health and alleviating the suffering of patients affected by respiratory and neonatal diseases. Programs and activities of the Chiesi Foundation are focused in some of the poorest areas in the world, where the Group does not have any production facilities or commercial activity.



See All

Access Accelerated Initiative

Tackling the growing burden of non-communicable diseases in low and middle-income countries and supporting...

Access Accelerated, Almirall, Astellas Pharma Inc, Bayer AG, Bristol-Myers Squibb, Celgene, Chiesi Farmaceutici, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, F. Hoffmann – La Roche Ltd., International Federation of Pharmaceutical Manufacturers & Associations, Johnson & Johnson, Menarini Group, Merck, MSD, Novartis, Pfizer Inc, Sanofi, Servier, Shionogi & Co., Ltd., Sumitomo Dainippon, Takeda Pharmaceutical Company Limited, UCB


See All